Table 5.
Clinical features of previously published cases of ovarian mesonephric-like adenocarcinoma.
| Author | No. of Cases | Age (yrs) | Presenting Symptom and Sign | Imaging Finding | Surgical Treatment | FIGO Stage | Recurrence | Status | Survival | OS (mos) |
|---|---|---|---|---|---|---|---|---|---|---|
| McFarland et al. [4]; Mirkovic et al. [5] | 5 | 42–62 (4/5); NA (1/5) | NA | NA | TH + BSO (2/5); BSO (1/5); NA (2/5) |
IA (1/5); IC (1/5); IIB (1/5); IIIC (1/5); NA (1/5) |
+(1/5); –(4/5) |
PD (1/5); NED (4/5) |
Alive (5/5) | 7–37 (4/5); NA (1/5) |
| Pors et al. [6] | 1 | 67 | NA | NA | NA | IC | NA | NA | NA | NA |
| Chapel et al. [7] | 1 | 80 | Abdominal pain | 12.5-cm pelvic mass, omental cake, mesenteric LNE, multiple hepatic nodules |
NAC + TH + BSO + O + P | IIIC | – | NED | Alive | 3 |
| McCluggage et al. [8] | 5 | 50–77 | Pelvic pain, vaginal discharge (1/5); NA (4/5) |
6-cm solid LO mass (1/5); NA (4/5) |
TH + BSO + PLND + O + P (1/5); NA (4/5) |
IIIA (1/5); NA (4/5) | NA | NA | NA | NA |
| Pors et al. [9] | 25 | 36–81 | Pelvic pain (10/25); uterine bleeding (4/25); abdominal distension or bloating (4/25); incidental (5/25); NA (2/25) |
NA | NA | I (11/25); II–IV (7/25); NA (7/25) |
+(10/25); –(14/25); NA (1/25) |
NA | 68% (PFS), 71% (OS) (23/25); NA (2/25) | 1–1346 |
| Dundr et al. [10] | 1 | 61 | NA | Non-resectable LO mass, hepatic metastases, peritoneal carcinomatosis |
NAC + TH + BSO + O + P + A | IVB | – | NED | Alive | NA |
| Seay et al. [11] | 1 | 67 | Pelvic heaviness, polyuria |
11-cm complex RA mass | TH + RSO + PLND + O | IA | + | SD | Alive | NA; 18 (RFS) |
| Chen et al. [12] | 1 | 29 | Abdominal discomfort |
10-cm solid and cystic RA and 5-cm cystic LA masses |
TH + BSO + PLND + PALND + O | IC | – | NED | Alive | 13 |
| da Silva et al. [13] | 15 | 36–76 | NA | NA | NA | IA (2/15); IC (3/15); IIB (2/15); IIIA (1/15); IIIC (2/15); IV (3/15); NA (2/15) |
+(10/15); –(5/15) |
NA | NA | NA |
| Deolet et al. [14] | 4 | 33–75 | Acute abdominal pain, hydronephrosis, bilateral pleural effusions (1/4); NA (3/4) |
7-cm LO mass (1/4); 15-cm solid and cystic LO mass (1/4); ovarian mass (1/4); 11-cm RO mass (1/4) | LSO (1/4); TH + BSO + O (1/4); BSO (1/4); right partialoophorectomy (1/4) |
IA (1/4); IC (1/4); IIIC (1/4); IVB (1/4) |
+(1/4); –(3/4) |
PR (1/4); NED (3/4) |
Alive (4/4) | 8–46 |
| Kim et al. [37] | 1 | 47 | Pelvic mass | 4.4-cm solid and cystic LO mass | PLND + PALND + O+P | IIIC | – | NED | Alive | 11 |
Abbreviations: A, appendectomy; BSO, bilateral salpingo-oophorectomy; LA, left adnexa; LNE, lymph node enlargement; LO, left ovary; LSO, left salpingo-oophorectomy; mos, months; NA, not applicable; NAC, neoadjuvant chemotherapy; NED, no evidence of disease; O, omentectomy; OS, overall survival; P, peritonectomy; PD, progressive disease; PFS, progression-free survival; SD, stable disease; RA, right adnexa; RFS, recurrence-free survival; RO, right ovary; TH, total hysterectomy; yrs, years; +, present; –, absent. Numbers enclosed in parenthesis in each cell indicate the number of positive cases per total cases reported in each article.